Immuron 将来の成長

Future 基準チェック /26

Immuron収益と収益がそれぞれ年間22.4%と59.7%増加すると予測されています。

主要情報

22.4%

収益成長率

n/a

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	59.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	26 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

Immuron suspends research on COVID-19 program

Aug 19

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Jul 26

Immuron to get European patent for drug composition to treat bacterial infection

Jul 07

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Dec 15

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Nov 11

業績と収益の成長予測

NasdaqCM:IMRN - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	15	-4	N/A	N/A	1
6/30/2025	6	-8	N/A	N/A	1
6/30/2024	5	-7	-6	-6	N/A
3/31/2024	4	-5	-5	-5	N/A
12/31/2023	4	-4	-4	-4	N/A
9/30/2023	3	-4	-3	-3	N/A
6/30/2023	2	-4	-3	-3	N/A
3/31/2023	1	-3	-2	-2	N/A
12/31/2022	1	-3	-2	-2	N/A
9/30/2022	1	-3	-2	-2	N/A
6/30/2022	1	-3	-3	-3	N/A
3/31/2022	1	-4	-3	-3	N/A
12/31/2021	0	-4	-4	-4	N/A
9/30/2021	0	-6	-4	-4	N/A
6/30/2021	0	-8	-4	-4	N/A
3/31/2021	1	-8	N/A	N/A	N/A
12/31/2020	1	-7	-4	-4	N/A
9/30/2020	2	-5	-4	-4	N/A
6/30/2020	3	-3	-3	-3	N/A
3/31/2020	3	-4	N/A	N/A	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	3	-5	-2	-2	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	2	-4	-1	-1	N/A
12/31/2018	2	-3	-1	-1	N/A
9/30/2018	2	-3	-2	-2	N/A
6/30/2018	2	-3	-4	-4	N/A
3/31/2018	2	-4	N/A	-6	N/A
12/31/2017	2	-5	N/A	-8	N/A
9/30/2017	2	-6	N/A	-8	N/A
6/30/2017	1	-7	N/A	-7	N/A
3/31/2017	1	-8	N/A	-5	N/A
12/31/2016	1	-6	N/A	-4	N/A
9/30/2016	1	-6	N/A	-5	N/A
6/30/2016	1	-7	N/A	-5	N/A
3/31/2016	1	-5	N/A	-5	N/A
12/31/2015	1	-4	N/A	-5	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	1	-3	N/A	-3	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-2	N/A	-3	N/A
9/30/2014	1	-2	N/A	-3	N/A
6/30/2014	1	-2	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	0	-3	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IMRN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IMRN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IMRN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IMRNの収益 ( 59.7% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: IMRNの収益 ( 59.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IMRNの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Immuron 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Immuron Limited, Annual General Meeting, Oct 28, 2022

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron suspends research on COVID-19 program

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Immuron to get European patent for drug composition to treat bacterial infection

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘